Summary
The antidepressive efficacy of l-deprenyl (5–10 mg daily) plus l-phenylalanine (250 mg/day) has been evaluated in 155 unipolar depressed patients. Both oral and intravenous administration showed beneficial effects in 90% of outpatients and 80.5% of inpatients. It is concluded that this combined treatment has a potent antidepressive action based on the accumulation of l-phenylethylamine in the brain.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Beckmann, H., Strauss, M. A., Ludolph, E.: DL-Phenylalanine in depressed patients: an open study. J. Neural Transm.41, 123–134 (1977).
Bein, H. J.: Rauwolfia and biological psychiatry. TINS5, 37–39 (1982).
Birkmayer, W.: Experimentelle Befunde und neue Aspekte bei extrapyramidalen Erkrankungen. Wien. Zeitschr. f. Nervenheilkunde13, 128–139 (1966).
Birkmayer, W., Neumayer, E., Stöckl, W., Weiler, G.: Defizit essentieller Aminosäuren bei endogener Depression. Wien. klin. Wschr.80, 832–834 (1968).
Birkmayer, W., Neumayer, E., Riederer, P.: Masked depression in old age. In: Masked Depression (Kielbolz, P., ed.) pp. 158–166. Bern-Stuttgart-Wien: H. Huber. 1973.
Birkmayer, W., Riederer, P.: Parkinson's Disease. Wien-New York: Springer. 1983.
Blackwell, B.: Hypertensive crises due to monoamine oxidase inhibitors. Lancetii, 849–851 (1963).
Boulton, A., Milward, L.: Separation, detection and quantitative analysis of urinary beta-phenylethylamine. J. Chromatogr.57, 287–296 (1971).
Caroll, B. J.: Monoamine precursors in the treatment of depression. Clin. Pharm. Ther.12, 743–761 (1971).
Elsworth, J. D., Glover, V., Reynolds, G. P., Sandler, M., Lee, A. L., Phaupradit, P., Shaw, K. M., Stern, G. M., Kumar, P.: Deprenyl administration in man. Selective monoamine oxidase B inhibitor without the “cheese effect”. Psychopharmacol.57, 33–38 (1978).
Fischer, E., Spatz, H., Heller, B., Reggiani, H.: Phenylethylamine content of human urine and rat brain, its alteration in pathological conditions and after drug administration. Experientia28, 307 (1972).
Fischer, E., Heller, B., Nachon, M., Spatz, H.: Therapy of depression by phenylalanine. Arzneimittel-Forsch. (Drug Res.)25, 132 (1975).
Glover, V., Sandler, M., Owen, F., Riley, G. J.: Dopamine is a monoamine oxidase-B substrate in man. Nature (Lond.)265, 80–81 (1977).
Hamilton, M.: A rating scale for depression. J. Neurol. Neurosurg. Psychiat.23, 56–61 (1960).
Inwang, E. E., Mosnaim, A. D., Sabelli, H. C.: Isolation and characterization of phenylethylamine and phenylethanolamine from human brain. J. Neurochem.20, 1469–1473 (1973).
Knoll, J., Ecsery, Z., Nievel, J., Knoll, B.: Phenylisopropyl-methylpropinylamin HCI. E-250 egy új hatásspektrumu pszichoenergetikum. MTA V. Oszt. Közl.15, 231 (1964).
Knoll, J., Magyar, K.: Some puzzling effects of monoamine oxidase inhibitors. In: Monoamine Oxidase — New Vistas (Advances in Biochemical Psychopharmacology, Vol. 5) (Costa, E., Sandler, M., eds.), pp. 393–408. New York: Raven Press. 1972.
Knoll, J.: Analysis of the pharmacological effects of selective monoamine oxidase inhibitors. In: Monoamine Oxidase and Its Inhibition (Ciba Foundation Symposium 39, new series), pp. 135–161. Amsterdam-Oxford-New York: Elsevier-Excerpta Medica-North-Holland. 1976.
Mann, J., Gershon, S.: Deprenyl, a selective monoamine oxidase type B inhibitor in endogenous depression. Life Sci.26, 877–882 (1980).
Mendis, N., Pare, C. M. B., Sandler, M., Glover, V., Stern, G.: (-)Deprenyl in treatment of depression. In: Monoamine Oxidase Inhibitors — The State of the Art (Youdim, M. B. H., Paykel, E. S., eds.), pp. 171–176. Chichester: Wiley. 1981.
Mendlewicz, J., Youdim, M. B. H.: Anti-depressant potentiation of 5-hydroxytryptophan by L-deprenyl, an MAO type B inhibitor. J. Neural Transm.43, 279–286 (1978).
Mendlewicz, J., Youdim, M. B. H.: L-Deprenil, a selective monoamine oxidase type B inhibitor, in the treatment of depression: a double blind evaluation. Brit. J. Psychiat.142, 508–511 (1983).
Reynolds, G. P., Riederer, P., Sandler, M., Jellinger, K., Seemann, D.: Amphetamine and 2-phenylethylamine in post-mortem parkinsonian brain after (-)deprenyl administration. J. Neural Transm.43, 271–277 (1978).
Varga, E., Tringer, L.: Clinical trial of a new type promptly acting psychoenergetic agent (phenylisopropylmethylpropinyl-HCl. E-250). Acta Med. Acad. Sci. Hung.23, 289–295 (1967).
Yang, H.-Y. T., Neff, N. H.: ß-Phenylethylamine: a specific substrate for type B monoamine oxidase of brain. J. Pharmacol. Exp. Ther.187, 365–371 (1973).
Youdim, M. B. H., Finberg, J. P. M.: Monoamine oxidase inhibitor antidepressants. In: Psychopharmacology 1 (Grahame-Smith, D. G., ed.), pp. 39–70. Amsterdam-Oxford-Princeton: Excerpta Medica. 1983.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Birkmayer, W., Riederer, P., Linauer, W. et al. L-deprenyl plus l-phenylalanine in the treatment of depression. J. Neural Transmission 59, 81–87 (1984). https://doi.org/10.1007/BF01249880
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF01249880